Insider Selling: Natera (NASDAQ:NTRA) Insider Sells 3,405 Shares of Stock

Key Points

• Solomon Moshkevich sold 3,405 Natera shares on May 1 at an average price of $203.69 (proceeds ~$693,564), reducing his stake to 142,295 shares (a 2.34% decrease).
• The sale was executed under a pre‑arranged Rule 10b5‑1 plan to cover tax withholding and follows several recent disposals by the same insider in March and April, indicating an ongoing, planned selling program.
• Natera recently reported an earnings beat (EPS $0.35 vs. consensus -$0.46) and revenue of $665.5M, the stock trades near $206.77, and analysts have an average "Moderate Buy" rating with a mean price target of $253.47.

Natera, Inc. (NASDAQ:NTRA - Get Free Report) insider Solomon Moshkevich sold 3,405 shares of the business's stock in a transaction on Friday, May 1st. The shares were sold at an average price of $203.69, for a total transaction of $693,564.45. Following the transaction, the insider directly owned 142,295 shares of the company's stock, valued at approximately $28,984,068.55. This trade represents a 2.34% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Solomon Moshkevich also recently made the following trade(s):

• On Monday, April 27th, Solomon Moshkevich sold 2,182 shares of Natera stock. The shares were sold at an average price of $204.10, for a total transaction of $445,346.20.
• On Wednesday, April 1st, Solomon Moshkevich sold 3,000 shares of Natera stock. The shares were sold at an average price of $202.30, for a total transaction of $606,900.00.
• On Tuesday, March 10th, Solomon Moshkevich sold 915 shares of Natera stock. The shares were sold at an average price of $204.13, for a total transaction of $186,778.95.
• On Monday, March 2nd, Solomon Moshkevich sold 3,000 shares of Natera stock. The shares were sold at an average price of $199.85, for a total transaction of $599,550.00.

Natera Stock Performance

Shares of NTRA traded down $4.79 during midday trading on Tuesday, hitting $206.77. 1,065,445 shares of the stock traded hands, compared to its average volume of 1,321,366. Natera, Inc. has a 1-year low of $131.81 and a 1-year high of $256.36. The firm has a market capitalization of $29.42 billion, a PE ratio of -135.14 and a beta of 1.57. The business's 50 day moving average price is $201.91 and its two-hundred day moving average price is $214.51.

Natera (NASDAQ:NTRA - Get Free Report) last announced its quarterly earnings results on Thursday, February 26th. The medical research company reported $0.35 earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.46) by $0.81. Natera had a negative net margin of 9.03% and a negative return on equity of 15.28%. The company had revenue of $665.50 million during the quarter, compared to the consensus estimate of $600.68 million. During the same quarter in the previous year, the company posted ($0.41) earnings per share. As a group, equities research analysts forecast that Natera, Inc. will post -1.71 EPS for the current fiscal year.

Institutional Investors Weigh In On Natera

Institutional investors have recently bought and sold shares of the stock. Reflection Asset Management bought a new stake in Natera in the fourth quarter worth about $29,000. Palladiem LLC bought a new stake in Natera in the fourth quarter worth about $31,000. Bank of Jackson Hole Trust raised its position in Natera by 103.8% in the fourth quarter. Bank of Jackson Hole Trust now owns 163 shares of the medical research company's stock worth $37,000 after acquiring an additional 83 shares in the last quarter. International Assets Investment Management LLC raised its position in Natera by 132.9% in the first quarter. International Assets Investment Management LLC now owns 170 shares of the medical research company's stock worth $35,000 after acquiring an additional 97 shares in the last quarter. Finally, Kemnay Advisory Services Inc. bought a new stake in Natera in the fourth quarter worth about $39,000. Institutional investors and hedge funds own 99.90% of the company's stock.

Analyst Ratings Changes

Several equities research analysts recently weighed in on NTRA shares. Wall Street Zen raised shares of Natera from a "hold" rating to a "buy" rating in a report on Saturday, April 18th. Guggenheim upped their price objective on shares of Natera from $230.00 to $270.00 and gave the stock a "buy" rating in a report on Monday, January 5th. Weiss Ratings reaffirmed a "sell (d-)" rating on shares of Natera in a report on Tuesday, April 21st. Robert W. Baird upped their price objective on shares of Natera from $239.00 to $257.00 and gave the stock an "outperform" rating in a report on Friday, February 27th. Finally, Wells Fargo & Company upped their price objective on shares of Natera from $205.00 to $215.00 and gave the stock an "equal weight" rating in a report on Friday, February 27th. One equities research analyst has rated the stock with a Strong Buy rating, fourteen have assigned a Buy rating, three have issued a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat, the stock currently has an average rating of "Moderate Buy" and an average price target of $253.47.

About Natera

Natera is a global diagnostics company that develops and commercializes cell-free DNA and other genetic testing technologies for clinical applications. The company focuses on three principal areas: reproductive health (including non-invasive prenatal testing and carrier screening), oncology (tumor-informed assays for minimal residual disease and recurrence monitoring), and organ transplantation (cell-free DNA tests to detect allograft injury). Natera combines laboratory testing, proprietary bioinformatics, and clinical reporting to deliver personalized genetic information to clinicians and patients.

Key product offerings include Panorama, a non-invasive prenatal test that screens for fetal chromosomal abnormalities and select single-gene conditions; Horizon carrier screening for inherited conditions; Signatera, a personalized, tumor-informed assay used for detecting minimal residual disease and monitoring treatment response in cancer patients; and Prospera, a donor-derived cell-free DNA test used to assess the risk of organ rejection.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.